Navigation Links
PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations
Date:6/1/2009

SOUTH PLAINFIELD, N.J., June 1 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that Clare Kennedy has been appointed as Vice President of Commercial Operations. In this role, she will report to Theresa Natalicchio, Senior Vice President, Commercial, and will be responsible for PTC's patient services and distribution functions focusing on product access and reimbursement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"We are delighted to welcome Clare to our management team," said Ms. Natalicchio. "Clare's extensive expertise in national healthcare customer management, contracting and distribution will be a great asset as we expand our commercial organization and prepare for the launch of ataluren."

"I am excited to join PTC," commented Ms. Kennedy. "The company has shown an exemplary advancement of its diverse pipeline and I look forward to being part of the commercial organization with a goal to bring PTC's innovative therapies to patients."

Prior to joining PTC, Ms. Kennedy spent 16 years at Pfizer, most recently as Vice President of Account Planning, overseeing national account management, customer contracting and product access in the U.S. for the company's $21 billion portfolio. Ms. Kennedy was responsible for U.S. sales in various areas including commercial health plans, pharmacy benefit management companies, long-term care, employers, and federally-funded programs. Prior to Pfizer, Ms. Kennedy started several small businesses involved in preventive health care and clinical research. She received an A.A.S. in Nursing from Long Island College Hospital, a B.S. in Health Science from St. Francis College and a M.S. in Health Management from the American University School of Business and College of Arts and Sciences. Ms. Kennedy is also a Registered Nurse.

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control of RNA processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology, and infectious diseases. PTC has extensive knowledge of post-transcriptional control processes and has developed proprietary technologies that it applies in its drug discovery activities internally and in collaborations with leading biopharmaceutical companies such as Genzyme, Pfizer, Celgene, Gilead and Schering-Plough. For more information, visit the company's Web site at www.ptcbio.com.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
2. TorreyPines Therapeutics Announces its Board of Directors Approval of Plan of Liquidation and Dissolution
3. Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics Amends Modified Dutch Auction Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes
7. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
8. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
9. Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
10. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
11. Orexigen(R) Therapeutics to Present at Upcoming Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... June 22, 2016 Research and Markets has ... report to their offering. ... 2014 from $29.3 billion in 2013. The market is expected to ... from 2015 to 2020, increasing from $50.6 billion in 2015 to ... forecasts during the forecast period (2015 to 2020) are discussed. As ...
Breaking Biology Technology:
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):